Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (Nasdaq: CTKB) is a cell analysis solutions company focused on high-parameter flow cytometry using its patented Full Spectrum Profiling™ (FSP®) technology. This news page aggregates coverage of Cytek’s announcements so readers can follow developments related to its instruments, reagents, services and corporate activities.
Company press releases frequently address financial results and outlook, including quarterly revenue performance, recurring revenue trends from service and reagent businesses, and updates on installed instrument base. Cytek also issues news when it provides preliminary revenue expectations or reaffirms full-year guidance, and these items are often accompanied by Form 8-K filings summarizing results of operations.
Another major category of CTKB news involves product and technology updates. Recent communications have highlighted the launch of the Cytek Aurora™ Evo full spectrum flow cytometer, enhancements to small particle detection, and initiatives to expand access to advanced cytometry tools through instrument awards and research grants. The company also reports on the use of its FSP systems in peer-reviewed research and at scientific meetings.
Investors and researchers will also find corporate and recognition news, such as Cytek’s inclusion on TIME’s 2026 list of America’s Growth Leaders, expansion of its European headquarters in Amsterdam, and participation in healthcare and investor conferences hosted by organizations including UBS, Morgan Stanley, Stephens and Piper Sandler. Updates on collaborations with groups like the International Society for Advancement of Cytometry (ISAC) and presence at clinical cytometry conferences such as ESCCA and ICCS are also covered.
By reviewing CTKB news, users can track how Cytek communicates its financial performance, product evolution, geographic expansion and engagement with the scientific and investment communities over time.
Cytek Biosciences (Nasdaq: CTKB) will report its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow on the same day at 2:00 p.m. PT to discuss the results and future outlook. Cytek is a leader in cell analysis solutions, known for its Full Spectrum Profiling™ (FSP™) technology, which enhances cell analysis precision and multiplexing capabilities. Its FSP platform includes instruments like Aurora and Northern Lights™ and reagents tailored for research purposes only. For more details, visit their investor relations website.
Cytek Biosciences (Nasdaq: CTKB) will host its inaugural Analyst and Investor Day on June 22, 2022, starting at 9:00 a.m. ET. This event aims to showcase Cytek's proprietary cell analysis technologies and related market opportunities, featuring presentations from industry leaders and Q&A sessions with the leadership team. A live webcast of the event will be available on Cytek’s investor relations website, and a replay will follow. Cytek specializes in Full Spectrum Profiling technology, enhancing cell analysis tools.
Cytek Biosciences has announced the availability of its CE-IVD-certified cFluor reagents for clinical diagnostics across Europe. This certification allows Cytek to expand its market presence and offer total cell analysis solutions in hospitals and laboratories. The reagents are produced under rigorous quality controls and validated for optimal performance with Cytek's advanced cell analysis systems. CEO Dr. Wenbin Jiang emphasized the significance of this milestone, indicating a commitment to enhancing diagnostic capabilities across the region.
Cytek Biosciences reported a strong first quarter for 2022, with total revenue reaching $35.1 million, marking a 44% increase year-over-year. The installed base grew to 1,226 instruments after placing 116 instruments in the quarter. Gross profit also rose to $20.2 million, though the gross profit margin slipped to 58% from 60% in 2021. Operating expenses climbed to $22.5 million, leading to a $2.4 million loss from operations. The company forecasts full-year revenue at the high end of $160 million to $168 million.
Cytek Biosciences (Nasdaq: CTKB) will report its Q1 2022 financial results after market close on May 11, 2022. Following the earnings announcement, management will host a webcast conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, business developments, and future outlook. Cytek is known for its Full Spectrum Profiling™ technology, providing advanced cell analysis solutions.
Cytek Biosciences announces the appointment of Todd Garland as Chief Commercial Officer, effective immediately. Garland, with extensive experience in the life sciences sector, previously held leadership roles at BD Biosciences, CareFusion, and Cardinal Health. His expertise is expected to enhance Cytek's growth and customer service capabilities centered around their Full Spectrum Profiling™ (FSP™) technology. Dr. Wenbin Jiang, CEO, believes Garland's leadership will be pivotal in executing growth opportunities and fortifying the organization’s market position in cell analysis.
Cytek Biosciences reported a 38% revenue growth for 2021, totaling $128 million. In Q4, revenue reached $38.9 million, a 27% increase from 2020. Although gross profit increased to $79.1 million for the year, operating expenses surged by 84% to $70 million, resulting in a decrease in income from operations. Net income fell to $4.4 million for 2021. The company plans for 2022 revenue between $160 million and $168 million and has expanded its manufacturing capacity significantly.
FREMONT, Calif., Feb. 16, 2022 – Cytek Biosciences (Nasdaq: CTKB) announces its participation in the 42nd Annual Cowen Health Care Conference. Management will engage in a fireside chat on March 9th at 8:10 a.m. PT / 11:10 a.m. ET. Interested participants can access the live and archived webcast via the Investors section of Cytek's website.
Cytek is a leader in cell analysis solutions, utilizing its Full Spectrum Profiling™ technology for high-resolution and high-sensitivity analysis. Its platform includes the Aurora and Northern Lights™ systems, and products are primarily for research use.
Cytek Biosciences (CTKB) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call, scheduled for 2:00 p.m. Pacific Time, will discuss the results and future outlook. Cytek is known for its Full Spectrum Profiling™ (FSP™) technology, enhancing cell analysis with high-resolution and sensitivity. The Aurora and Northern Lights systems are central to Cytek’s offerings. Note that most products are for research use only, except for Northern Lights CLC, which is cleared for clinical use in China and the EU.
Cytek Biosciences, Inc. (Nasdaq: CTKB) has opened a new 100,000 square-foot facility in Fremont, California, tripling its manufacturing capacity to accommodate rising global demand for cell analysis solutions. The facility became operational in October 2021 and supports the company's commitment to advancing cell analysis technology. Cytek aims to enhance its offering of integrated solutions, leveraging its patented Full Spectrum Profiling™ (FSP™) technology. With over 1,000 instruments installed across 40 countries, Cytek continues to innovate in the life sciences sector.